Table 1.
Baseline characteristics, severity and therapeutic interventions.
| Control | Nintedanib | P Value | |
|---|---|---|---|
| N = 30 | N = 30 | ||
| Age, years | 70 (62–77) | 75 (66–80) | 0.109 |
| Sex, male | 18 (60%) | 23 (76.7%) | 0.165 |
| BMI (kg/m2) | 23.2 (20.9–25.5) | 24.6 (20.3–27.9) | 0.756 |
| Pre-existing conditions | |||
| Hypertension | 16 (53.3%) | 19 (63.3%) | 0.432 |
| Chronic respiratory disease | 4 (13.3%) | 12 (40%) | 0.020 |
| Chronic heart failure | 2 (6.7%) | 7 (23.3%) | 0.071 |
| Chronic kidney disease | 6 (20%) | 5 (16.7%) | 0.739 |
| Diabetes mellitus | 13 (43.3%) | 12 (40%) | 0.793 |
| Cancer | 1 (3.3%) | 4 (13.3%) | 0.161 |
| Charlson comorbidity index | 2 (0–3) | 2 (1–4) | 0.143 |
| Findings at time of intubation | |||
| Glasgow Coma Scale score | 13 (6–15) | 11 (3–15) | 0.789 |
| Body temperature (°C) | 37.4 (36.8–37.7) | 37.1 (36.4–37.6) | 0.176 |
| PaO2/FiO2 ratio | 181 (120–242) | 178 (121–255) | 0.487 |
| White blood cell count (103/μL) | 7.1 (5.6–9) | 7 (3.7–11.9) | 0.756 |
| Platelet count (103/μL) | 171 (131–256) | 165 (125–209) | 0.217 |
| C-reactive protein (mg/dL) | 11.8 (7.8–18.2) | 10.1 (6.7–15.8) | 0.174 |
| Creatinine (mg/dL) | 0.9 (0.6–1.1) | 0.9 (0.8–1.2) | 0.243 |
| Bilirubin (mg/dL) | 0.6 (0.5–0.8) | 0.6 (0.4–0.9) | 0.917 |
| APACHE II score | 17 (11–21) | 17 (13–24) | 0.358 |
| SOFA score | 7 (4–8) | 7 (5–10) | 0.480 |
| ISTH overt-DIC score | 0 (0–2) | 0 (0–2) | 0.963 |
| Therapeutic interventions | |||
| Corticosteroids | 26 (86.7%) | 29 (96.7%) | 0.161 |
| Favipiravir | 27 (90%) | 23 (76.7%) | 0.166 |
| V-V ECMO | 4 (13.3%) | 3 (10%) | 0.688 |
| Prone position | 12 (40%) | 14 (46.7%) | 0.602 |
| Unfractionated heparin | 24 (80%) | 28 (93.3%) | 0.129 |
BMI, body mass index; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; ISTH, International Society on Thrombosis and Hemostasis; DIC, disseminated intravascular coagulation; V-V ECMO, veno-venous extracorporeal membrane oxygenation.